INTRODUCTION

Cells either migrate or proliferate, but not both at the same time, a phenomenon termed migration-proliferation dichotomy. The underlying mechanism of this phenomenon has remained unknown. We demonstrate here that Gαi and GIV, its nonreceptor guanine nucleotide exchange factor (GEF), program EGFR receptor (EGFR) signaling and orchestrate this dichotomy. GIV directly interacts with EGFR, and when its GEF function is intact, a Gαi–GIV–EGFR signaling complex assembles, EGFR autophosphorylation is enhanced, and the receptor’s association with the plasma membrane (PM) is prolonged. Accordingly, PM-based motogenic signals (PI3-kinase-Akt and PLCγ1) are amplified, and cell migration is triggered. In cells expressing a GEF-deficient mutant, the Gαi–GIV-EGFR signaling complex is not assembled, EGFR autophosphorylation is reduced, the receptor’s association with endosomes is prolonged, mitogenic signals (ERK 1/2, Src, and STAT5) are amplified, and cell proliferation is triggered. In rapidly growing, poorly motile breast and colon cancer cells and in noninvasive colorectal carcinomas in situ in which EGFR signaling favors mitosis over motility, a GEF-deficient splice variant of GIV was identified. In slow growing, highly motile cancer cells and late invasive carcinomas, GIV is highly expressed and has an intact GEF motif. Thus, inclusion or exclusion of GIV’s GEF motif, which activates Gαi, modulates EGFR signaling, generates migration-proliferation dichotomy, and most likely influences cancer progression.

Previous work has established that growth factor receptors such as EGF (Chen et al., 1994a,b), VEGF (Gerhardt et al., 2003), and PDGF (De Donatis et al., 2008) receptors, can trigger both mitoty and mitosis and that the type and concentration of the activating ligand and the abundance and distribution of receptor influence whether cells migrate or divide. In migrating cells, a distinct set of signals (phospholipase C [PLC]γ1 and PI3-kinase [PI3K]) are amplified and coupled to actin remodeling within pseudopods at the leading edge. In proliferating cells, another set of signals (MAP kinase [MAPK]/ERK1/2, and c-Src/STAT5b) are amplified, which leads to activation of nuclear transcription factors that drive DNA synthesis during mitosis (Haugh, 2002; Kloth et al., 2003). Ligand stimulation initiates both sets of signals, which are rapidly modulated in the immediate postreceptor phase such that migration and mitosis are executed in a mutually exclusive manner (Chen et al., 1994b; De Donatis et al., 2008). Little is known about how cells responding to growth factors make this decision.

We recently discovered a novel non-receptor GEF for Gαi, GIV, a.k.a. Girdin (Garcia-Marcos, et al., 2009). Activation of Gαi by GIV is required for growth factors (EGF and insulin) to trigger cell migration during epithelial wound healing, macrophage chemotaxis, and tumor cell migration (Ghosh et al., 2008). Others implicated GIV/Girdin in development of retinal and tumor blood vessels (Kitamura et al., 2008) and in cancer invasion and metastasis (Jiang et al., 2008) based on its promigratory effects on cells responding to VEGF and insulin-like growth factor (IGF). We have shown that the
GEF motif within GIV’s C terminus, which specifically binds and activates Gai subunits (Garcia-Marcos et al., 2009, 2010) is the critical component of GIV that is required for cell migration. Activation of Gai releases “free” Gβγ subunits, thereby enhancing Akt signaling via the Gβγ–PI3K pathway. Because Gai and GIV constitute a key regulatory complex within the growth factor signaling network during cell migration (Ghosh et al., 2008), we investigated whether GIV’s GEF function and ability to activate Gai can influence cells to preferentially migrate or proliferate by regulating the EGFR receptor (EGFR), the prototype member of the growth factor receptor tyrosine kinase family.

MATERIALS AND METHODS

Additional experimental protocols and methods are provided in the Supplemental Data.

Reagents and Antibodies

Unless otherwise indicated, all reagents were of analytical grade and obtained from Sigma-Aldrich (St. Louis, MO). Cell culture media were purchased from Invitrogen (Carlsbad, CA). Activated GEFRG kinase and phospho-tyrosine monoclonal antibody (mAb) were purchased from Cell Signaling Technology (Danvers, MA). Silencer Negative Control #1 small interfering RNA (siRNA) and siRNA Gai3 were purchased from Ambion (Austin, TX) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Vector Laboratories (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Cell Signaling Technology (Danvers, MA). Silencer Negative Control #1 small interfering RNA (siRNA) and siRNA Gai3 were purchased from Ambion (Austin, TX) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Vector Laboratories (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.

Cell culture media were purchased from Invitrogen (Carlsbad, CA). Activated GEFRK kinase and phospho-tyrosine monoclonal antibody (mAb) were purchased from Cell Signaling Technology (Danvers, MA). Silencer Negative Control #1 small interfering RNA (siRNA) and siRNA Gai3 were purchased from Ambion (Austin, TX) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Vector Laboratories (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Vector Laboratories (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. Streptavidin-horseradish peroxidase (HRP), biotinylated EGF, and mouse submaxillary EGF were purchased from Vector Laboratories (Burlingame, CA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.
Immunoprecipitation, Binding Assays, and In Vitro Phosphorylation

Cell lysates (~1–2 mg of protein) were incubated 4 h at 4°C with either 2 μg of anti-EGFR (9225) mAb (endogenous EGFR), anti-FLAG mAb (Sigma-Aldrich) (FLAG-EGFR), and their respective preimmune control IgGs. Protein G-agarose beads (Invitrogen) were added and incubated at 4°C for an additional 60 min. Beads were washed then either resuspended and boiled in SDS sample buffer, or beads were incubated with purified His-GIV-CT (aa 1623–1870) overnight, washed, and then resuspended and boiled in SDS sample buffer. For immunoprecipitations involving ligand-activated EGFR, buffers used during all steps of the process were supplemented with 100 μM sodium orthovanadate.

For experiments investigating direct interaction between GIV and EGFR, recombinant EGFR kinase (Cell Signaling Technology) was used to phosphorylate the native GIV C terminus (EGFR-T, aa 1064–1210) in vitro according to the manufacturer’s protocol. In brief, equal aliquots of GST and GST-EGFR-T were incubated with 5 ng purified kinase in the presence of 200 μM ATP (Sigma-Aldrich) at room temperature for 60 min before their use in binding assays.

In the in vitro binding assays using GST-fusion proteins were carried out as described previously (Ghosh et al., 2008). In brief, purified GST-fusion proteins (15–20 μg) or GST alone (30 μg) were immobilized on glutathione-Sepharose beads and resuspended in binding buffer supplemented with nucleotides (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.4% [vol/ vol], NP-40, 10 mM MgCl₂, 5 mM EDTA, 2 mM DTT, and protease inhibitor cocktail supplemented with either 30 μM GDP or 30 μM guanine diphosphate [GDP] (Sigma-Aldrich) and 10 mM NaF) (Ghosh et al., 2008). The entire “[S]Met (GE Healthcare)-labeled GST preparation were incubated with the Trn Quick Coupled Transcription/Translation System (Promega, Madison, WI) was added to the binding buffer and binding was carried out overnight at 4°C with constant tumbling. The following day, the beads were washed (4.3 mM Na₃HPO₄·1.4 mM KH₂PO₄·pH 7.4, 137 mM NaCl, 2.7 mM KCl, 61% [vol/ vol] Tween 20, 10 mM MgCl₂, 5 mM EDTA, and 2 mM DTT), and boiled in sample buffer for SDS-polyacrylamide gel electrophoresis. For Gα3, the wash buffer was supplemented with GDP or GDP, GDP, and NaF during binding.

Reverse Transcription (RT)-PCR
Total RNA was isolated from each cell line using the RNeasy Mini Kit (QIAGEN, Valencia, CA). First-strand cDNA was generated by RT-PCR using the Superscript First Strand Synthesis System for RT-PCR (Invitrogen). Primers were designed using Invitrogen’s oligoperfect Designer and evaluated with NetPrimer from Premierbiosoft. Positioning of primers was dependent on the target domains of GIV we intended to amplify (primer sequences are available upon request). Glycereraldehyde-3-phosphate dehydrogenase (GAPDH; Allele Biotechnology and Pharmaceuticals, San Diego, CA) mRNA amplified from the same samples served as an internal control. Thirty-five cycles of PCR were carried out across all experiments using Life Technologies Taq DNA Polymerase (Invitrogen). PCR products were visualized, photographed (Chemi Doc XRS; Bio-Rad Laboratories), and quantified using Quantity One SW software (Bio-Rad Laboratories). For sequence analysis (DNA Sequencing Facility, UCSD Moore’s Cancer center), PCR products were purified using QIAquick (QIAGEN). To rule out contamination due to genomic DNA, RT-PCR minus reactions were run as a one step reaction using total RNA for PCR, eliminating the step of cDNA synthesis using reverse transcriptase. To rule out gene fusion events at the C terminus of GIV, rapid amplification of cDNA ends (3′ RACE kit; Invitrogen) reactions were carried out on some of the cell lines (HT29, LS174T, and MCF7). To determine the strength of 19th intron as a splice site, the donor and acceptor splice sites were scored by the Splice Site Prediction program by Neural Networks (http://www.fruitfly.org/seq_tools/splice.html), which takes other known splicing sequences into account.

Statistical Analysis
Each experiment presented in the figures is representative of at least three independent experiments. Statistical significance (p value) between various conditions was assessed with the Student’s t test. All graphical data presented was prepared using GraphPad software (GraphPad Software, San Diego, CA).

RESULTS

GIV’s GEF Function and Gai Activation Lead to Decreased Proliferation and Increased Migration

To investigate how GIV’s GEF function affects cell migration and proliferation, we used live cell imaging to compare the behavior of HeLa cells stably expressing either siRNA-resistant wild-type GIV (GIV-wt cells) or a GEF-deficient GIV F1685A mutant (GIV-FA cells) incapable of interacting with or activating the G protein (Garcia-Marcos et al., 2009). Endogenous GIV was depleted in both cell lines using previously validated siRNA oligonucleotides (Enomoto et al., 2005; Ghosh et al., 2008). Cells were stimulated with EGF in combination with scratch wounding, and both migration and proliferation at the wound edge were simultaneously monitored by live cell imaging. We found that GIV-wt cells typically migrated into the wound, whereas GIV-FA cells showed reduced migration but ~50% more mitotic events at the wound edge (Supplemental Movies 1 and 2; Figure 1A). Both GIV-wt and GIV-FA cells maintained their distinct behavior with (Figure 1A) or without (Supplemental Figure S1C) depletion of endogenous GIV, indicating that the GEF-deficient GIV F1685A mutant behaves as a dominant-negative protein. The mitotic index as determined by levels of phospho-histone H3, an indicator of mitosis (Hans and Dimitrov, 2001), was consistently high in GIV-FA cells, intermediate in control (untransfected) cells, and low in GIV-wt cells after scratch wounding (Supplemental Figure S2, A and B). Analysis of growth curves at steady state confirmed that expression of GIV-wt suppressed, whereas expression of GIV-F1685A enhanced cell proliferation (data not shown). Thus, in the absence of GIV’s GEF function, cells display decreased motility but increased proliferation. Overall these results demonstrate that upon growth factor stimulation, cells with an intact GEF motif preferentially migrate, whereas cells with a disrupted GEF motif preferentially proliferate.

Because GIV-wt and GIV-FA cells differ by a single point mutation that specifically disrupts GIV’s GEF activity and prevents activation of Gα3 (Garcia-Marcos et al., 2009), we asked whether G protein activity alone is sufficient to create this phenotypic dichotomy. We stimulated HeLa cells expressing YFP-tagged Gα3-wt or the constitutively inactive Gα3-G203A (GA) or active (GTPase-deficient) Gα3-Q204L (QL) mutant (Hermouet et al., 1991) by scratch wounding, and then we monitored cell motility and division simultaneously by live cell imaging. We found that cells expressing Gα3-wt-YFP and Gα3-QL-YFP frequently displayed polarized migration into the wound but rarely (~3%) underwent mitosis, whereas in cells expressing the inactive Gα3 mut, cell migration was reduced by ~50% and mitosis was increased sixfold (Supplemental Movies 3 and 4; and Figure 1B). These findings demonstrate that migration is triggered and proliferation is suppressed when GIV’s GEF function is intact or and Gα3 is constitutively active. By contrast, when GIV’s GEF function is selectively disrupted and Gα3 is inactive, proliferation is triggered and migration is suppressed. Together, these results suggest that Gα3 activity as determined by the GEF domain of GIV is a critical determinant of cellular preference for migration versus proliferation.

GIV’s GEF Function Regulates EGFR Signaling

Next we assessed the effects of disrupting GIV’s GEF function on EGF signaling. GIV-wt, GIV-FA, and control HeLa cells were stimulated with EGF and analyzed by immunoblotting for activation (phosphorylation) of four major EGFR-stimulated signals—Akt, PLCγ1, ERK1/2 MAPK, and c-Src/STAT5b (Haugh, 2002; Kloth et al., 2003). GIV-wt cells showed enhanced Akt and PLCγ1 phosphorylation but attenuated STAT5b and ERK1/2 phosphorylation, whereas GIV-FA cells showed the opposite, i.e., enhanced Akt and PLCγ1 phosphorylation and decreased STAT5b and ERK1/2 phosphorylation. Overall these results suggest that GIV’s GEF function is a critical determinant of cellular preference for migration versus proliferation.

GIV’s GEF Function Regulates EGFR Signaling

Next we assessed the effects of disrupting GIV’s GEF function on EGF signaling. GIV-wt, GIV-FA, and control HeLa cells were stimulated with EGF and analyzed by immunoblotting for activation (phosphorylation) of four major EGFR-stimulated signals—Akt, PLCγ1, ERK1/2 MAPK, and c-Src/STAT5b (Haugh, 2002; Kloth et al., 2003). GIV-wt cells showed enhanced Akt and PLCγ1 phosphorylation but attenuated STAT5b and ERK1/2 phosphorylation, whereas GIV-FA cells showed the opposite, i.e., enhanced ERK1/2 and STAT5b but attenuated Akt and PLCγ1 signaling (Figure 1C and D). c-Src activity, as determined by dephosphorylation of pY527 on Src, which coincides with entry into mitosis (Bagrodia et al., 1991), was decreased in GIV-wt and increased in GIV-FA cells compared with controls (Figure 1,
Figure 1. A Gqi–GIV complex imparts migration-proliferation dichotomy by modulating motogenic and mitogenic signals initiated by EGFR. (A) GIV-wt cells preferentially migrate, whereas GIV-FA cells preferentially proliferate. Confluent monolayers of HeLa cells stably expressing either siRNA-resistant wild-type GIV (GIV-wt) or GEF-deficient GIV (GIV-FA) (see Supplemental Figure S1) were depleted of endogenous GIV, starved for 6–12 h in 0.2% FBS, scratch wounded, and then treated with 0.1 nM EGF. The edge of the wound was monitored by live cell imaging for 12 h (see Supplemental Movies 1 and 2). The total number of cells along the edge of the wound that demonstrated polarized migration into the wound or completed cell division in response to EGF were counted and expressed as the percent of cells analyzed. Bar graphs display the percent of GIV-wt versus GIV-FA cells that migrate (above) or divide (below) during the first 12 h. Results are shown as mean±SEM (n = 14 to 15 randomly chosen fields from one representative experiment). (B) Active Gqi3 (Q204L) promotes migration, whereas inactive Gqi3 (G203A) promotes mitosis. HeLa cells transfected with Gqi3wt-YFP, Gqi3(QL)-YFP, or Gi3(GA)-YFP were grown to confluence and stimulated by scratch wounding in the presence of 10% serum to initiate EGFR signaling (Tetreault et al., 2007). Cells were then imaged for 8 h as they migrated into the wound (see Supplemental Movies 3 and 4; as in A). Bar graphs display the percent of cells at the edge of the wound that migrate or divide. Results are shown as mean±SEM (n = 25 to 30 randomly chosen fields from 2 to 3 independent experiments). (C and D) GIV-wt cells enhance PLCγ1 and Akt and suppress c-Src, ERK1/2, and STAT5b signals in response to EGF, whereas GIV-FA cells show the opposite signaling profile. (C) Serum-starved GIV-wt, GIV-FA, and control (untransfected) HeLa cells were stimulated with 50 nM EGF, and whole cell lysates were analyzed for total (t)- and phospho (p)-PLCγ1, c-Src, Akt, ERK1/2, and STAT5b and actin by immunoblotting (IB). (D) Kinetics of EGF-initiated signaling pathways in HeLa cell lines determined by phospho-protein:actin ratios at each time point after EGF stimulation and expressed as fold increase in activation normalized to t = 0 min. Although all three cell lines achieved similar enhancement of phosphorylation of PLCγ1 at 5 min, this enhancement was sustained in GIV-wt but rapidly reduced in GIV-FA cells by 15 min. For STAT5b, phosphorylation was enhanced and sustained up to 30 min GIV-FA cells but not in GIV-wt cells. Inhibitory phosphorylation of Src at Y527 was increased in GIV-wt and suppressed in GIV-FA, but the ligand-dependent variations seen in control cells were lost in GIV-wt and GIV-FA cells. Phosphorylation of Akt was enhanced (peak at 5 min) in GIV-wt and suppressed in GIV-FA cells. Finally, the peak activity of ERK1/2 at 5 min was suppressed in GIV-wt but enhanced.
C and D). These distinct signaling profiles were also seen in GIV-wt and GIV-FA cells depleted of endogenous GIV (Supplemental Figure S3A), indicating that the differences in signaling were a direct consequence of the presence or absence of a functional GEF motif. Contrasting profiles of Akt and ERK1/2 activation were also evident when GIV-wt and GIV-FA cells were stimulated by scratch wounding (data not shown), indicating that selective signal amplification occurs irrespective of the mode of receptor activation. These results demonstrate that the presence of the GEF motif in GIV-wt cells leads to amplification of Akt and PLCγ1 signals that are predominantly motogenic (i.e., required for motility) and concomitantly suppresses c-Src/STAT5b and ERK1/2 signals that are predominantly mitogenic, whereas mutation of the GEF domain in GIV-FA cells leads to a mirror image response (Figure 1E). We conclude that GIV’s C-terminal GEF motif, which activates Gai (Garcia-Marcos et al., 2009), is the critical component of the decision to migrate or proliferate.

**GIV’s GEF Function Regulates EGFR Phosphorylation and Recruitment of Scr Homology (SH2)-Adaptors**

EGFR signaling to downstream effectors is mediated through ligand-induced tyrosine autophosphorylation of the EGFR tail and SH2 adaptor recruitment to the resultant phosphotyrosines (Schlessinger, 2002). We next investigated whether GIV’s GEF activity regulates these two early events in EGFR signaling. Serum starved GIV-wt, GIV-FA, and control HeLa cells were stimulated with EGF, and EGFR autophosphorylation was assessed at Y992, Y1045, and Y1068, (docking sites of the SH2 adaptors, PLCγ1, cCbl, and Grb2) and at Y845 (the substrate for c-Src kinase that triggers mitosis; Tice et al., 1999), using site-specific phospho-Tyr antibodies (Figure 2A). Promigratory GIV-wt cells displayed enhanced EGFR autophosphorylation at Y992, Y1045, and Y1068, whereas Src-dependent phosphorylation at Y845 was similar to controls (Figure 2, B and C; and Supplemental Figure S3B). By contrast, proliferative GIV-FA cells showed attenuated EGFR autophosphorylation at Y992, Y1045, and Y1068 but sustained phosphorylation at Y845 (Figure 2, B and C; and Supplemental Figure S3B). These results demonstrate that GIV’s GEF function is required to enhance EGFR autophosphorylation and that in the absence of a GEF motif the receptor is preferentially phosphorylated by c-Src.

SH2-adaptor recruitment to the above autophosphorylation sites on the EGFR tail (Figure 2A) was evaluated in GIV-wt versus GIV-FA cells by immunoprecipitating the receptor and analyzing the receptor-bound complexes for Grb2, c-Cbl, and phospho-PLCγ1 by immunoblotting. On ligand stimulation, recruitment of phospho-PLCγ1, c-Cbl, and Grb2 to ligand-activated EGFR was increased in GIV-wt and decreased in GIV-FA cells compared with controls (Figure 2, D–H). These results demonstrate that the GIV’s GEF activity affects two of the earliest events in EGFR signaling—receptor phosphorylation and SH2 adaptor recruitment, indicating that the Gai–GIV complex may function at the level of the receptor tail as well as the immediate postreceptor phase.

**GIV’s GEF Function Is a Key Determinant of EGFR Localization and Degradation**

The distribution of ligand-activated EGFR between the plasma membrane (PM) and endosomes is known to affect EGFR signaling (Haugh, 2002) in that motogenic PI3K and PLCγ signals are initiated by ligand-activated receptor largely or exclusively at the PM, whereas mitogenic MAPK-ERK1/2 and c-Src signals can be propagated from endosomes (Murphy et al., 2009). To find out whether the different signaling profiles we observed in GIV-wt and GIV-FA cells are accompanied by differences in distribution of EGFR we compared the localization of ligand-bound EGFR in GIV-wt and GIV-FA cells. Cell surface EGFR was labeled in chilled (4°C), serum-starved cells using HRP-tagged EGF (Razi and Futter, 2006), after which cells were warmed to 37°C for 15 min and then fixed and analyzed for the distribution of the ligand (HRP-EGF)-bound receptor by immunofluorescence. To selectively visualize ligand-bound receptor at the PM, HRP staining was carried out without detergent permeabilization, whereas to visualize both the PM and internalized pools permeabilization was performed before staining. At 0 min, GIV-wt, GIV-FA, and control cells showed a similar pattern and intensity of HRP-EGF labeling on the cell surface, indicating that these cells have similar amounts of EGFR available at the surface for ligand binding (Figure 3A, a–c). However, at 15 min after ligand stimulation a larger pool of ligand-bound EGFR remained as punctate staining on the PM in GIV-wt cells (Figure 3Ae) compared with controls (Figure 3Ad), whereas EGFR was virtually undetectable at the PM in GIV-FA cells (Figure 3Af), and most of the receptor was found in internal compartments (Figure 3A, i and l). To establish the nature of these compartments, we cotained HRP-EGF (Figure 3B, a–c) or EGFR [using anti-EGFR mAb; Burke et al., 2001] (Figure 3Bd) with markers of early (EEA1) or late (Ct-MPR; data not shown) endosomes. We found that both HRP-EGF and the receptor colocalized with EEA1, indicating that in GIV-FA cells the ligand-bound receptor was in early endosomes. These data indicate that although there were similar amounts of receptor on the surface at steady state (Figure 3A, a–c), upon ligand stimulation the duration and extent of receptor association with the PM is enhanced in GIV-wt and decreased in GIV-FA cells. In the latter, the receptor is rapidly (within 15 min) compartmentalized within EEA1–positive early endosomes. Similar results were obtained with either high (50 nM) or low (0.1 nM) concentrations of EGFR or when cells were stimulated by scratch wounding (data not shown). At later time points after ligand stimulation (60 min), a significant amount of the receptor was still detectable in the juxtanuclear region in GIV-FA but not in GIV-wt cells (Figure 3C). When total EGFR was quantified by immunoblotting at 30 min after ligand stimulation, ~20% remained in GIV-wt, ~40% in controls, and ~74% in GIV-FA cells (Figure 3D and Supplemental Figure S3B). Thus, GIV-wt promotes and GIV-FA slows EGFR degradation. Together, these results indicate that GIV’s GEF activity enhances the receptor pool at the PM but promotes EGFR degradation upon internalization. When the GEF function is disrupted, the cell surface pool of receptor is reduced, the receptor stays longer in endosomes, and degradation of the receptor is delayed. Thus, GIV’s GEF motif regulates both spatial and temporal aspects of EGFR signaling.
Gαi, GIV, and EGFR Form a Ligand-regulated Signaling Complex

Based on our findings that disruption of the Gαi-GIV interaction affects EGFR signaling and localization, we investigated whether GIV and/or Gai interacts with EGFR. When we immunoprecipitated EGFR from HeLa (Figure 4A) and Cos7 (Supplemental Figure S4A) cells and immunoblotted for Gai3 and GIV, both Gai3 and GIV coimmunoprecipitated with endogenous EGFR. GIV interacted with the receptor under both starved (lane 2) and EGF-stimulated (lane 3)
conditions, and ligand stimulation increased GIV–EGFR complexes. By contrast Gaia3 interacted only after EGF stimulation, suggesting that ligand stimulation is required for recruitment of Gaia3. These results demonstrate the existence of a Gaia3–GIV–EGFR complex in vivo. Moreover, by confocal microscopy ligand-activated EGFR partially colocalized with GIV (Figure 4B) and Gaia3 (Figure 4C and Supplemental 54B) at the PM in HeLa cells (analyzed using scatter plots), suggesting that the Gaii-GIV-EGFR signaling complexes form at the PM.

Next, we asked whether the N terminus (GIV-NT) or the C terminus (CT) of GIV participates in formation of the Gaia3–GIV–EGFR complex. We found that GIV-NT (aa 1–1354) communoprecipitated with EGFR under both starved conditions and after EGF stimulation (Figure 4D, lanes 2 and 3). By contrast, GIV-CT (aa 1623–1870), which contains the crucial actin binding (Enomoto et al., 2005) and GEF (Garcia-Marcos et al., 2009) domains, bound only after EGF stimulation (Figure 4E, lane 5). Thus, the interaction between GIV-NT and EGFR is constitutive, whereas the interaction between GIV-CT and EGFR occurs exclusively upon receptor activation. These results support the following model (Figure 4F): In the starved state, GIV couples to EGFR via its NT, and upon ligand stimulation the GIV-EGFR interaction is reinforced by additional recruitment of GIV’s CT.

To investigate whether GIV-CT or Gaia3 directly binds to activated EGFR, we used in vitro-phosphorylated, GST-tagged cytoplasmic tail of EGFR (EGFR-T) in pull-down assays with purified His-GIV-CT or His-Gaia3. We found that the phosphorylated EGFR-T directly bound GIV-CT (Figure 4F, last lane) but not Gaia3 (Figure 4G, last lane), suggesting that the Gaia3-EGFR interaction seen in vivo (Figure 4A) is indirect.

GIV’s GEF Motif Couples G Protein Activity to EGFR Signaling

To investigate whether the GEF motif in the C terminus of GIV participates in the formation of the Gaia3–GIV–EGFR complex, we immunoprecipitated EGFR from GIV-wt and GIV-FA cells and analyzed the receptor-bound proteins for Gaia3 by immunoblotting. In GIV-wt cells, EGFR transiently and maximally associated with Gaia3 at 15 min after ligand stimulation, whereas in GIV-FA cells Gaia3 recruitment was virtually abolished (Figure 4H). Thus, EGFR–Gaia3 complexes form only when GIV’s GEF motif is intact, indicating that EGFR and the G protein are probably linked via GIV (Figure 4I).

GIV’s GEF Activity Is Dysregulated in Cancer Cells

EGFR signaling has been implicated in the generation of migration-proliferation dichotomy during cancer invasion (Athale et al., 2005). Previously, we demonstrated that GIV’s GEF function is required for the prometastatic properties of cancer cells (Garcia-Marcos et al., 2009) and that full-length GIV (GIV-fl) is expressed in some but not all cancer cells (Ghosh et al., 2008). Here, we investigated whether the presence or absence of GIV’s GEF function differentiates slow growing, highly motile colon cancer cells from rapidly growing, poorly motile cells. Using an antibody against the C-terminal 19 aa of GIV, we detected GIV-fl (∼250 kDa) in slowly growing highly motile/highly invasive (LDL1 and HCT-116) cells but not in rapidly growing poorly motile colon cancer cells (Lelièvre et al., 1998; Brattain et al., 1999) with low invasiveness (HT29 and LS174T) (Figure 5A). When we analyzed these cells for expression of GIV-fl mRNA by RT-PCR using two C-terminal GIV domain-specific primers (CT and G binding domain [GBD]) (Supplemental Figure S5A), we found that wherever GIV-fl protein was undetectable the transcript was also virtually abolished (Figure 5A). Similar results were obtained on three breast cancer cell lines with different growth and invasive potential (Howlin et al., 2008): GIV-fl (protein and mRNA) was expressed only in slow-growing, highly motile/invasive cells and undetectable in fast-growing, poorly motile cells with low invasiveness (Figure 5B), whereas levels of Gaia3 were equal. In contrast, a GIV-fl transcript was always detected in normal colon and breast epithelia (Supplemental Figure S5, B and C). Further comparison of the abundance of PCR products (GBD through C terminus) in an extended set of cells revealed that across three different carcinomas GIV-fl was consistently up-regulated ∼3- to 30-fold in highly invasive cells and down-regulated ∼5- to 12-fold in poorly invasive cells (Figure 5C). We confirmed that the up-regulated GIV message in highly invasive cells is wild-type in sequence and that the translated protein selectively binds Gaia3 in the presence of GDP, but not GDP·AlF4- (data not shown), indicating that GIV retains its properties as a nonreceptor GEF (Garcia-Marcos et al., 2009). These results indicate that altered expression of GIV, but not Gaia3, is the key feature that determines whether a functional complex can be assembled in vivo: GIV can interact with Gaia3 in slow-growing, highly motile/invasive cells that express GIV-fl, but not in fast-growing, poorly invasive cells that suppress GIV-fl.

In Fast-growing, Poorly Invasive Cancer Cells, GIV Is Replaced by GIVACT, a Truncated Variant Lacking the C-Terminal GEF Motif

Because metastasis-related genes often undergo alternative splicing leading to aberrant expression (Weber, 2008; Srebrn and Kornblith, 2006), we asked whether dysregulation of GIV-fl expression occurs due to alternative splicing. Using RT-PCR and a series of oligonucleotide primers, we investigated the N terminus of GIV and detected transcripts of predicted size (∼250 base pairs) and sequence in highly invasive cancer cells and their respective normal controls (Figure 6A and Supplemental Figure S6B). In poorly invasive colon (LS174T and HT29) and breast (MCF7) cancer cells, this product was either accompanied by or virtually replaced by an additional, larger (∼1250-base pair) PCR
product (Figure 6A and Supplemental Figure S6A). This larger PCR product appeared only when primer pairs flanked the 19th intron. Thus, we suspected that the amplified RNA transcript is the product of an alternative splicing event due to failure of processing and resultant retention of the 19th intron. We confirmed this by sequence analysis and named the aberrant transcript GIV-intron retention 19 (GIV-IR19). In poorly invasive cells, the abundance of GIV-IR19

Figure 3. GIV’s GEF function prolongs EGFR localization at the PM but enhances degradation upon internalization. (A) At 15 min after ligand (HRP-EGF) stimulation, ligand-bound EGFR localizes at the PM (e, arrowheads in h) in GIV-wt cells and within intracellular compartments (i and l) in GIV-FA cells. Starved control, GIV-wt, and GIV-FA cells were labeled and stimulated with 300 nM HRP-EGF (equivalent to 50 nM EGF) at 4°C (0 min), washed with PBS, and warmed to 37°C for 15 min. They were then fixed and costained with or without prior permeabilization for HRP, EEA1, and nucleus/DAPI, and visualized by confocal microscopy. Staining for HRP without permeabilization allows selective visualization of ligand-bound receptor at the PM (a–f), whereas permeabilization allows visualization of both the PM and intracellular pools of receptor (g–l). Bar, 10 μm. (B) In GIV-FA cells, EGFR maximally colocalizes with EEA1-positive endosomes at 15 min. GIV-FA cells were stimulated with HRP-EGF for 15 min as in Figure 3A, visualized by confocal microscopy, and analyzed for colocalization of EEA1 (green; a) and HRP (red; b) using Volocity software. The yellow pixels (c) showed significant overlap (Pearson’s correlation = 0.45) between HRP-EGF and EEA1. Identical results were obtained when the C terminus of EGFR was stained instead of the ligand (arrows in d). Bar, 10 μm. (C) At 60 min after ligand stimulation, EGFR is virtually undetectable in GIV-wt cells (e and h) but significant staining is seen in GIV-FA cells (f and i) compared with controls (d and g). Cells were stimulated with 50 nM EGF for 60 min and costained for EEA1 (green), tEGFR (red; anti-EGFR cytoplasmic tail), and the nucleus/DAPI (blue). Bar, 10 μm. (D) EGFR degradation is delayed in GIV-FA cells. Serum-starved control, GIV-wt, and GIV-FA HeLa cells were stimulated for 30 min with 50 nM EGF as in Figure 1C and analyzed for total EGFR (tEGFR, anti-EGFR cytoplasmic tail) and actin by immunoblotting (IB; top). Band-shifts and doublets are consistently detected that correlate with phosphorylation of EGFR. Bottom, the amount of receptor (180 kDa, full length) present at 30 min was quantified by Odyssey infrared imaging, normalized to actin, and expressed as percent remaining compared with 0 min. Results are shown as mean ± SEM.
Figure 4. Goi3, GIV, and EGFR form a ligand-regulated complex. (A) Endogenous Goi3 and GIV coimmunoprecipitate with EGFR. Serum-starved HeLa cells were stimulated with 50 nM EGF for 5 min before lysis. Immunoprecipitation was carried out on equal aliquots of cell lysates (left) using anti-EGFR (#225, Lanes 2 and 3) and pre-immune (Lane 1) IgGs, and the bound immune complexes were analyzed for tEGFR, Goi3, and GIV by immunoblotting (IB; right). Receptor activation was confirmed by immunoblotting for pEGFR (Y845). (B) Endogenous GIV and EGFR partially colocalize at the cell periphery upon ligand stimulation. Starved HeLa cells were stimulated with EGF for 5 min, fixed, stained for pY845 EGFR (a; green), GIV (b; red), and the nucleus/DAPI (blue) and analyzed by confocal microscopy. Merged image (c) shows patches at the PM where GIV and EGFR colocalize (yellow, arrowheads; Pearson’s correlation = 0.50; overlap coefficient = 0.50). Inset in d is a scatter-plot of red and green pixels at the PM, generated using Volocity software. Bar, 10 μm. (C) Endogenous Goi3 and EGFR partially colocalize at the cell periphery upon ligand stimulation. Starved HeLa cells were treated as described in B and stained for activated (pY845) EGFR (a; green), Goi3 (b; red), and the nucleus/DAPI (blue), and analyzed by confocal microscopy. Merged image (c) shows patches at the PM where Goi3 and EGFR colocalize (arrowheads, yellow; Pearson’s correlation = 0.69; overlap coefficient = 0.69). A scatter plot (d) of red and green pixels at the PM was generated as described in B, Bar, 10 μm. (D) GIV’s N terminus constitutively interacts with EGFR. Cos7 cells cotransfected with FLAG-EGFR and a truncated GIV construct (GIV-NT) lacking the C terminus (~520 aa) were serum starved or treated with EGF, and immunoprecipitation was carried out on cell lysates using anti-FLAG IgG. Left, Cos7 lysates (Input) show expression of GIV-NT and FLAG-EGFR by immunoblotting (IB). RIGHT: Immunoprecipitates analyzed for EGFR and GIV-NT by IB. GIV-NT interacts with EGFR both before (lane 2) and after (lane 3) EGF stimulation. (E) GIV’s C terminus (GIV-CT) interacts only with activated EGFR. FLAG-EGFR was immunopurified from starved (SS) or stimulated (EGF) Cos7 cells as described in D followed by incubation of the bead-bound receptor with purified His-GIV-CT (aa 1623–1870) overnight. Bound proteins were analyzed for FLAG-EGFR, His-GIV-CT, and Goi3, and actin by IB. Goi3-3XFLAG (lane 6), which is known to interact with GIV-CT (Garcia-Marcos et al., 2009), was used as a positive control. His-GIV-CT binds to the activated EGFR (lane 5) and Goi3 (lane 6), but not to the inactive receptor (lane 4). (F and G) The C terminus of GIV directly interacts with the phosphorylated cytoplasmic tail of EGFR (EGFR-T). Equal aliquots (15 μg) of GST or GST-EGFR-T (aa 1064–1210) were phosphorylated in vitro using 5 ng of recombinant EGFR kinase and used in pull-down assays with purified His-GIV-CT (aa 1660–1870) (F) or His-Goi3 (G). Bound proteins were visualized by IB for His, and phosphorylation of EGFR was confirmed by immunoblotting for pTyr. Phosphorylated but unphosphorylated GST-EGFR-T directly binds His-GIV-CT (F; right lane) but not His-Goi3 (G; right lane). (H) GIV’s GEF motif is required for ligand-stimulated recruitment of Goi3 and actin to EGFR. Lysates prepared from EGF-stimulated GIV-wt and GIV-FA cells (as described in Figure 1C) were incubated with anti-EGFR (#225) IgG (as described in Figure 2D–G), and immune complexes were analyzed by tEGFR, phosphorylated (pY845) EGFR, Goi3, and actin by IB. Goi3 and actin coimmunoprecipitated with EGFR in GIV-wt (top) but not in GIV-FA cells (bottom) at 5 and 15 min. (I) Working model summarizing findings in A–H. In the starved state, GIV interacts with inactive EGFR (left) through its N terminus, whereas activation of EGFR (right) triggers a regulated interaction between the receptor tail and GIV’s C terminus, thereby coupling the receptor tail to G protein signaling at the PM. NT and CT domains of GIV and the G protein are illustrated (bottom).

was inversely proportional to that of GIV-fl—the higher the percentage of intron retention (IR; Figure 6B), the less GIV-fl mRNA (Figure 5C) or protein (Figure 5, A and B). These results indicate that in poorly invasive cells, IR effectively disrupted translation resulting in down-regulation of GIV-fl expression, a phenomenon known to occur in other instances during oncogenesis (Dreyfuss et al., 2002).

GIV-IR19 contains an in-frame stop codon within the retained 19th intron (Figure 6C) and is predicted to translate into a truncated protein without the C terminus. We asked whether this aberrant splice variant is translated in fast-growing, poorly invasive cells. Although GIV-fl was undetectable using GIV-CTAb that recognizes the C terminus (Figure 5, A and B), a ~135-kDa protein was detected with GIV-cc antibody which
recognizes the N-terminal coiled-coil domain (Le-Niculescu et al., 2005; Figure 6D) indicating that this variant lacks the C-terminus (GIV\textsuperscript{ΔCT}). We assessed if GIV\textsuperscript{ΔCT}, which lacks the C-terminal GEF motif (Garcia-Marcos et al., 2009), could bind Goi3 in a pull-down assay, and, as anticipated, GIV\textsuperscript{ΔCT} did not bind Goi3 in vitro (Figure 6E); therefore, it is incapable of assembling a functional complex with Goi3 in vivo.

**GEF-deficient GIV\textsuperscript{ΔCT} Modulates EGFR Signaling, Inhibits Migration, and Enhances Proliferation**

To investigate the consequences of replacing GIV-fl with GIV\textsuperscript{ΔCT}, we generated a HeLa cell line expressing GIV\textsuperscript{ΔCT} in which the ratio of GIV-fl:GIV\textsuperscript{ΔCT} was identical to that found in poorly invasive MCF7 cells (intron retention, ~65%; Figure 6B). We found that cells expressing GIV\textsuperscript{ΔCT} behaved like cells expressing the GEF-deficient, dominant-negative GIV-F1685A mutant in that they migrated poorly (Figure 6F); failed to enhance Akt in scratch wound assays (Figure 6G); and grew more rapidly (Figure 6H) than GIV-wt and controls, indicating that lack of GIV’s C terminus renders cells immotile and highly proliferative. On stimulation with EGF, cells expressing GIV\textsuperscript{ΔCT} also displayed a signaling profile identical to that observed in GIV-FA cells, in that expression of GIV\textsuperscript{ΔCT} suppressed motogenic signals (Akt and PLC\textgamma{1}), enhanced mitogenic signals (ERK1/2 and STAT5b) (Figure 6I), suppressed EGFR-autophosphorylation (Figure 6J), and delayed receptor degradation (Figure 6K). Thus, disruption of the GEF function is the common denominator that accounts for the identical phenotypes of cells expressing GIV-FA or GIV\textsuperscript{ΔCT}.

Furthermore, exogenous expression of GIV-fl in poorly invasive MCF7 cells at high levels using plasmid cDNA (where introns are excluded) enhanced migration and Akt activity (data not shown), suggesting that when alternative splicing is bypassed, GIV-fl is translated and can enhance Akt signaling and trigger epithelial cell migration. GIV-fl induced migration in a dose-dependent manner and increased Akt activity (data not shown), demonstrating that expression of GIV-fl is necessary and sufficient to enhance Akt activation and trigger epithelial cell migration. These findings indicate that the presence or absence of GIV’s C-terminus containing its GEF motif can enable or disable Goi-GIV interaction and thereby trigger migration or mitosis in different cancer cells.

Figure 4. Continued.
Cells Expressing GEF-deficient GIVΔCT Predominate Early and Those Expressing GIV-wt Are Enriched Later during Progression of Colorectal Carcinomas

Next, we investigated whether alternative splicing of GIV’s C terminus takes place in tumors in vivo during cancer invasion—a process that relies heavily on EGFR signaling (Wells et al., 2002). We carried out immunohistochemistry (IHC) for GIV on paraffin-embedded human colorectal cancers representing various stages of invasive disease (Duke’s stages A through D, where A denotes locally restricted tumor without spread and D indicates the presence of distant macroscopic metastases). In normal colon, moderate amounts of GIV-fl as determined with GIV-CTAb were detected in epithelial cells lining the crypt bases (Supplemental Figure S7c). In the epithelia of noninvasive (Duke’s A) tumors (Figure 7A, a and b; and B) GIV-fl was virtually undetectable. Among tumors of intermediate stage (Duke’s B), ~50% expressed GIV-fl (Figure 7B), whereas all invasive tumors of advanced stages (Duke’s C and D) stained positive for GIV-fl (Figure 7B). In keeping with the previously reported high expression of GIV-fl in mesenchymal cells (Enomoto et al., 2005; Ghosh et al., 2008; Jiang et al., 2008; Kitamura et al., 2008), the stroma stained very strongly in both normal and cancer tissues (Figure 7A and Supplemental Figure S7b). Both normal and tumor tissue stained homogeneously positive for GIV’s N terminus using GIV-ccAb irrespective of their clinical stage (data not shown). Thus, noninvasive tumors stained positive for GIV’s N terminus, but not for GIV’s C terminus, and invasive tumors stained positive for both. These results validate that the phenomenon of alternative splicing observed in cancer cell lines also occurs in tumors in situ. As a result during early, noninvasive stages of tumor growth cells in which GIV is alternatively spliced to generate GEF-deficient GIVΔCT predominate, whereas during late invasive stages the proportion of cells that express full-length GIV progressively increases. These results indicate that expression of GIV-fl is first down-regulated by alternatively splicing to generate a GEF-deficient variant during tumor growth and then up-regulated during tumor invasion (Figure 7C).

DISCUSSION

A Gai–GIV Molecular Complex Establishes Migration-Proliferation Dichotomy

Here, we describe a novel role for GIV’s GEF domain and G protein activation in dictating whether cells migrate or pro-
liferate. We show that GIV-wt cells which contain a functional GEF motif and assemble a Gαi–GIV complex frequently migrate but rarely divide in response to EGF. By contrast, GIV-FA cells or GIVACT cells that express GEF-
deficient variants of GIV, which are defective in their ability to interact with or activate Gai (Garcia-Marcos et al., 2009), frequently divide but rarely migrate. Cells expressing active or inactive G3i mutants also display preferential motility or mitosis, respectively, indicating that Gai activation status is sufficient for dictating cellular decision making. Overall, these results indicate that the presence or absence of GIV’s GEF domain, which activates Gai, is the key to establishing this striking phenotypic dichotomy upon growth factor stimulation.

Previous work predicted a central role for EGFR in migration-proliferation dichotomy (Athale et al., 2005) and demonstrated that the signaling pathways that lead to motility or cell proliferation diverge at the immediate postreceptor phase (Chen et al., 1994b). We have defined the point of divergence by showing that when GIV is able to bind to the EGFR tail and activate Gai cells are biased to migrate. We further demonstrate that the phenotypic dichotomy imparted by the Gai–GIV complex stems from its ability to differentially amplify or attenuate signaling cascades initiated by EGFR. In response to EGF, GIV-wt cells show enhanced motogenic (PI3K and PLCγ1) and concomitantly suppressed mitogenic signals (ERK, STAT5b, and c-Src), whereas GIV-FA cells show the opposite. Our finding that G protein activity plays a key role in orchestrating this migration-proliferation dichotomy is also consistent with previous work demonstrating that migration is triggered by active G3i (Ghosh et al., 2008), but mitosis is enhanced by inactive Gai (Cho and Kehrl, 2007). We conclude that both G protein and growth factor signaling operate through GIV and participate in establishing migration-proliferation dichotomy and that the presence or absence of GIV-dependent Gai activation is crucial for it to take place. However, it currently remains unknown whether activation of Gai by GIV’s GEF motif eventually mediates its downstream effects via effectors of Gai and/or Gβγ subunits.

From these findings, we provide evidence that Gai and both the N and C termini of GIV participate in orchestrating phe-
notypic dichotomy in the cell’s response to growth factors. We found that cells in which GIV was depleted differed significantly in their signaling profile from those lacking the C terminus of GIV (GIV\(^{\text{CT}}\)) or those selectively lacking a functional C-terminal GEF motif (GIV-FA). In GIV\(^{\text{CT}}\) and GIV-FA cells, motogenic pathways are inhibited and mitogenic pathways are enhanced, whereas in cells depleted of endogenous full-length GIV both pathways are inhibited (Supplemental Figure S3A). These differences suggest that the C-terminal GEF motif is required to enhance motogenic and suppress mitogenic pathways; and that in its absence, the N terminus of GIV is sufficient to propagate mitogenic pathways. Based on the insights our results provide on the GIV-EGFR interaction (Figure 4E), we speculate that constitutive interaction between GIV’s N terminus and EGFR could contribute to such selective signaling. The nonselective suppression of signals we observe in cells without GIV may also explain why these cells were characterized previously as growth deficient and immotile (Anai et al., 2005; Enomoto et al., 2005). Similarly, we have shown that without Goi, GIV-dependent signaling and cell migration are inhibited (Ghosh et al., 2008), and cells are rendered proapoptotic (Ohman et al., 2002). We conclude that both Goi and GIV are required for cell migration and mitosis, however, activation of Goi by GIV biases the cells to migrate.

GIV’s GEF Function Links G Proteins to Growth Factor Receptors

Indirect stimulation of growth factor receptors by GPCR/G protein intermediates—so-called transactivation—is well established (Luttrell et al., 1999). Signaling via G proteins after direct stimulation of growth factor receptors has also been described previously (Waters et al., 2004; Dhanasekaran, 2006), but there is little mechanistic insight into how this could occur. Here, we provide evidence that GIV’s GEF motif can serve as a common platform for growth factor and G protein signaling by directly linking EGFR to Goi, sub-

**Figure 7.** In colorectal carcinomas, expression of GIV-fl is suppressed in early stages of noninvasive tumor growth and increased in late stages of tumor invasion. (A) Cells deficient in GIV-fl dominate noninvasive tumors, whereas those with increased GIV-fl are found in invasive tumors. Paraffin-embedded human colon cancer samples were analyzed for GIV-fl by immunohistochemistry using GIV-CTAb. Panels on the left display representative fields from either noninvasive (Duke’s A) tumors of early clinical stage (a and b) or invasive (Duke’s C/D) tumors of late clinical stages (c and d). Noninvasive Duke’s A tumor cells (T; a and b) stain negatively for GIV-fl whereas invasive Duke’s C and D tumors (c and d) are strongly positive (d). Stroma (S) consistently stained strongly positive in all tumors irrespective of their clinical stage/invasiveness. b and d are higher magnification views of the boxed regions on the left. (B) Percentage of GIV-fl-positive tumors increases with increasing clinical stage of colorectal carcinoma. GIV expression was analyzed in tumors (as in A) of variable clinical stages by three independent observers with >95% congruence. Bar graphs comparing the proportion of tumors that were scored as positive for full-length GIV expression within each Duke’s clinical stage: 0% for Dukes A, ~48% for B, and 100% for C and D. The total number of tumors examined within each clinical stage is indicated in parentheses. (C) Working model. Expression of GIV-fl undergoes bipartite dysregulation during oncogenesis. In some cancer cells (left), GIV is down-regulated by alternative splicing such that these cells cannot assemble functional Goi–GIV complexes and fail to activate Goi. Consequently, EGF signaling is programmed such that mitogenic signals are favored over motogenic pathways. This pattern of signal transduction triggers mitosis and suppresses migration/invasion. By contrast, in other cancer cells (right) the GIV-fl transcript and protein are up-regulated. In these cells functional Goi–GIV complexes are assembled, via which GIV activates Goi, and EGF-signaling is programmed such that motogenic signals are preferentially amplified over mitogenic pathways. This pattern of signal transduction triggers migration/invasion and suppresses mitosis in cells overexpressing GIV-fl. The highly proliferative cells in which GIV is down-regulated dominate the noninvasive tumor first and highly invasive cells in which GIV-fl is up-regulated are enriched later during metastatic invasion, suggesting that GIV may influence tumor growth and invasiveness during oncogenic progression.

Vol. 21, July 1, 2010 2351
units. We show that in starved cells GIV’s N terminus interacts with EGFR, and upon ligand stimulation the GIV-EGFR interaction is further strengthened by recruitment of GIV’s C terminus to the autophosphorylated EGFR tail and recruitment of Gai3 to the GIV–EGFR complex. This Gai–GIV–EGFR ternary complex is formed exclusively in GIV-wt, but not in GEF-deficient GIV-FA or GIVΔCT cells, indicating that GIV’s C-terminal GEF motif is required for Gai3 to interact with the activated EGFR. Consequently, efficient coupling of growth factor signaling to Gai-dependent Akt enhancement and actin remodeling occurs in GIV-wt cells but not in GIV-FA cells (Garcia-Marcos et al., 2009). Where on the receptor tail GIV binds and which phosphorylation events regulate this interaction remain unknown. Given that a variety of growth factors (VEGF, insulin, and IGF1) (Enomoto et al., 2006) trigger cell migration via GIV, it is possible that their receptors share a common mechanism.

The Gai–GIV Molecular Complex Regulates Temporal and Spatial Aspects of EGFR Signaling

We demonstrate that GIV’s GEF activity affects EGFR phosphorylation, distribution, and rate of degradation. We show that in highly motile GIV-wt cells with an intact GEF motif, EGFR autophosphorylation at Y992, Y1045, and Y1068 and the corresponding adaptor recruitment (PLCγ, cCbl, and Grb2) are enhanced, whereas in rapidly proliferating, GEF-deficient GIV-FA cells these events are suppressed. This is in keeping with a previous report that EGFR autophosphorylation is essential for motility but not for mitosis (Chen et al., 1994a).

The integrity of GIV’s GEF motif is a key determinant of both receptor distribution and downstream signaling pathways. In GIV-wt cells with an intact GEF motif, ligand-activated EGFR (visualized using HRP-EGF) remains at the PM for an extended period, but once internalized, receptor degradation is accelerated. When GIV’s GEF function is selectively disrupted (GIV-FA cells), EGFR is depleted at the PM, its association with endosomes is increased, and its degradation is delayed. We also show that upon EGFR stimulation, motogenic PI3K and PLCγ1 signals are selectively enhanced in GIV-wt cells and motility is triggered (Figure 1C), whereas in GIV-FA cells mitogenic c-Src-STAT5b/ERK1/2 signals are propagated, and proliferation is enhanced.

These differences in receptor localization and contrasting profiles of EGF- or GIV-FA cells in keeping with previous reports (Rijken et al., 1991; Haugh, 2002; Howlin et al., 2008; Iyer et al., 2008) that motogenic signals are initiated and coupled to actin remodeling exclusively by receptors at the PM to preferentially trigger motility, whereas internalized receptors preferentially propagate mitogenic signals, presumably from endosomes (Murphy et al., 2009). These differences in EGFR signaling have been attributed to the levels of phosphatidylinositol-4,5-bisphosphate (PI4,5P2), a critical and common substrate of the two key motogenic enzymes PI3K and PLCγ1, which are enriched at the PM but depleted at endosomes (Haugh, 2002). We conclude that motogenic PI3K and PLCγ1 signals are enhanced in the presence of an intact GEF motif, probably due to the persistence of activated receptor at the PI4,5P2-enriched PM, and inhibited in the absence of a GEF motif, probably due to accumulation of activated receptor in the PI4,5P2-depleted endosomes. That the rates of receptor degradation are accelerated in GIV-wt and delayed in GIV-FA cells may reflect a function of GIV in sorting and trafficking of EGFR (Simpson et al., 2005), perhaps modulated by differential recruitment of c-Cbl (Figure 2, A, E, and G), the ubiquitin ligase that promotes endosomal degradation of EGFR (Levkowitz et al., 1998).

The distribution of EGFR in GIV-FA cells (decreased at the PM but increased within endosomes) is strikingly similar to that reported previously in cells overexpressing c-Src (Ware et al., 1997). Moreover, we found that increased Src activity in GIV-FA cells is associated with sustained receptor phosphorylation at Y845, a c-Src substrate site, as well as hyper-activation of ERK1/2. Enhanced ERK1/2 activation in spite of reduced Grb2 recruitment could be mediated through Src (Frame, 2004). That highly motile GIV-wt cells restrict ERK activity to low levels is consistent with the computational analysis of proteomic networks of the EGFR pathway (Janes and Lauffenburger, 2006), which predicts that low ERK phosphorylation favors high-speed motility. Our results suggest that increased Src activity may contribute to the spatiotemporal changes in EGFR signaling and enhanced mitosis we observe in the absence of GIV’s GEF motif.

We demonstrate that in human breast and colon cancer cells the assembly of the Gai–GIV molecular complex depends on the differential expression of GIV’s GEF motif. In rapidly proliferating, poorly invasive cancer cell lines, GIV is alternatively spliced to produce a dominant-negative variant without the critical C terminus (GIVΔCT). Cells expressing GIVΔCT lack the GEF motif and cannot assemble the Gai–GIV complex. HeLa cells expressing GIVΔCT behave like GIV-FA cells in that they inhibit motogenic signals and selectively propagate mitogenic signals in response to EGF and are immotile and proliferate rapidly, features that facilitate early tumor growth (Bernards and Weinberg, 2002). In contrast, in highly invasive cancer cells expression of GIVΔ mRNA and protein is upregulated, and these cells behave like the GIV-wt HeLa cells in that they migrate efficiently (Howlin et al., 2008) via activation of Gai (Ghosh et al., 2008; Garcia-Marcos et al., 2009) but proliferate more slowly (Le- lievre et al., 1998; Howlin et al., 2008) and require GIV for efficient tumor invasion (Jiang et al., 2008). These features are known to hinder early tumor growth but are required later for metastatic progression (Bernards and Weinberg, 2002). To the best of our knowledge, this is the first example of a protein that undergoes bipartite dysregulation during oncogenesis: In slow-growing, highly invasive cancer cells constitutive splicing allows translation of GIV-fl and maintains high levels of GIV-fl mRNA and protein, whereas in rapidly growing, poorly invasive cells alternative splicing of GIV yields a GEF-deficient GIVΔCT variant and restricts GIV-fl mRNA and protein to low levels. This pattern of GIV expression in cancer cells with two different phenotypes is in keeping with the profiles of EGFR signaling and behavior we observe in our HeLa cell lines.

We also demonstrate that expression of GIVΔCT is restricted only to poorly invasive cancer cells. On subsequent analysis of the splice site, we found it to be “weak” based on the lack of homology to consensus mammalian splice signals (Supplemental Figure S6D). However, the weakness of the splice site alone cannot explain the missplicing event observed in poorly invasive breast and colon cancer cells because the sequence is recognized and this intron is efficiently
excised in healthy cells or their highly invasive variants (Figure 6A). In addition, mutations (within the 19th intron or the flanking exons) as a cause of aberrant pre-mRNA splicing were ruled out by sequencing. These results suggest that extrinsic factors, e.g., differential expression of splicing factors during cancer progression (Stickeler et al., 1999), may restrict GIVΔCT expression to poorly invasive cells. Regardless of the mechanism, splicing-mediated exclusion of GIV’s C-terminal GEF motif was a strikingly conserved theme in poorly motile cancer cells.

We also found that expression of GIV’s GEF motif is dysregulated in human colorectal tumors. Noninvasive tumors of early stages are largely comprised of cells that express GIVΔCT which endows cells with a proliferative advantage. With advancing clinical stages, invasive tumors are increasingly made up of cells expressing GIV-fl, which endows cells with an invasive advantage (Jiang et al., 2008). This shift in tumor composition is in keeping with studies demonstrating that phenotypic heterogeneity exists among cells within the same tumor (Giese et al., 1996; Fedotov and Iomin, 2007). Phenotypic heterogeneity has remained a challenge in treatment of carcinomas because only the actively proliferating cells are the most vulnerable to chemotherapy, whereas the nonproliferating cells that are actively invading are resistant to anticancer drugs (Mandel and Rall, 1969).

Our findings suggest that alternative splicing of GIV’s GEF motif probably contributes to phenotypic heterogeneity and influences early tumor growth as well as late metastatic invasion. In fact, our unpublished work indicates that tumors made up of cells expressing GIVΔCT have increased DNA microsatellite instability and tend to grow larger but are poorly invasive and carry a good prognosis, whereas those made up of cells expressing GIV-fl tend to metastasize early and are associated with poor survival.

In conclusion, we have described a novel molecular mechanism that regulates whether cells migrate or proliferate during cancer invasion. Mechanistic insights gained as to how GIV, a nonreceptor GEF, links G protein activity to growth factor receptor signaling helps define a new paradigm for how G proteins affect growth factor signaling and sheds light on the enigmatic origin of migration-proliferation dichotomy that is observed not only in cancer progression but also during epithelial wound healing and development.

ACKNOWLEDGMENTS

We thank Gordon N. Gill for anti-EGFR antibodies, scientific advice, and thoughtful comments during preparation of this manuscript; Howard Rockman for the FLAG-tagged EGFR construct; Roger Tsien (UCSD) for sharing his confocal microscope; and Paul Steinbach (UCSD) for assistance with microscopy and analysis software. We also thank the UCSD School of Medicine Light Microscopy Facility, supported in part by National Institutes of Health (NIH) Institute of Neurological Disorders and Stroke (NINDS) grants P30 NS-047101 and DK-80506 and its director, Jennifer Meerbaum. This work was funded by NIH grants CA-100768 and DK-17780 (to J. P. Holyoake), NINDS grants P30 NS-047101 and DK-17780 (to M. C. Frame), and Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDIN) (to P. G.), who was also supplemented by NIH grant T32 DK-07505 and its director, Jennifer Meerloom. This work was funded by NIH grants CA-100768 and DK-17780 (to M. C. Frame) and Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDIN) (to P. G.), who was also supplemented by NIH grant T32 DK-07505 and its director, Jennifer Meerloom. This work was funded by NIH grants CA-100768 and DK-17780 (to M. C. Frame) and Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDIN) (to P. G.), who was also supplemented by NIH grant T32 DK-07505 and its director, Jennifer Meerloom. This work was funded by NIH grants CA-100768 and DK-17780 (to M. C. Frame) and Burroughs Wellcome Fund and Research Scholar Award (American Gastroenterology Association FDIN) (to P. G.), who was also supplemented by NIH grant T32 DK-07505 and its director, Jennifer Meerloom.

REFERENCES

Anai, M., et al. (2005). A novel protein kinase B (PKB)/AKT-bonding protein enhances PKB kinase activity and regulates DNA synthesis. J. Biol. Chem. 280, 18525–18535.

Athale, C., Mansury, Y., and Deisboeck, T. S. (2005). Simulating the impact of a molecular ‘decision-process’ on cellular phenotype and multicellular patterns in brain tumors. J. Theor. Biol. 233, 469–481.

Auszlen, D. H., and Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14, 53–65.

Bagrodia, S., Chackalaparampil, I., Kmieciik, T. E., and Shalloway, D. (1991). Altered tyrosine 527 phosphorylation and mitotic activation of p60-src. Nature 349, 172–175.

Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, V., Cohen, C., Connolly, J., and Sager, R. (1990). Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res. 50, 7351–7357.

Bernards, R., and Weinberg, R. A. (2002). A progression puzzle. Nature 418, 823.

Bonneton, C., Sibarita, J. B., and Thierry, J. P. (1999). Relationship between cell migration and cell cycle during the initiation of epithelial to fibroblastoid transition. Cell Motil. Cytoskeleton 43, 288–295.

Brattain, M. G., Willson, J. K. V., Koterba, A., Patil, S., and Venkataseswarlu, S. (1999). Colorectal cancer. In: Human Cell Culture, Vol. 2, Cancer Cell Lines Part 2, ed. J. R. W. Masters and B. Falsson, London, United Kingdom: Kluwer Academic, 293–303.

Bresalier, R. S., Huguenin, E. S., Raper, S. E., Roff, F. J., Itzkowitz, S. H., Martin, G. R., and Kim, Y. S. (1987). An animal model for colon cancer metastasis: establishment and characterization of murine cell lines with enhanced liver-metastasizing ability. Cancer Res. 47, 1398–1406.

Burke, P., Schooler, K., and Wiley, H. S. (2001). Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12, 1897–1910.

Chen, P., Gupta, K., and Wells, A. (1994a). Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J. Cell Biol. 124, 547–555.

Chen, P., Xie, H., Sekar, M. C., Gupta, K., and Wells, A. (1994b). Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J. Cell Biol. 127, 847–857.

Cho, H., and Kehrl, J. H. (2007). Localization of Ga alpha proteins in the centrosomes and at the midbody: implication for their role in cell division. J. Cell Biol. 175, 245–255.

Chung, E. H., Hutcheon, A. E., Joyce, N. C., and Zieske, J. D. (1999). Synchro- nization of the G1/S transition in response to corneal debridement. Invest. Ophthalmol. Vis. Sci. 40, 1952–1958.

Dhanasekaran, D. N. (2006). Transducing the signals: a Ga protein takes a new identity. Sci. STKE 2006, pe31.

De Donatis, A., Comito, G., Buricchi, F., Vinci, M. C., Parenti, A., Caselli, A., Camici, G., Manaio, G., Ramponi, G., and Cirri, P. (2008). Proliferation versus migration in platelet-derived growth factor signaling: the key role of endo- cytosis. J. Biol. Chem. 283, 19948–19956.

Dreyfuss, G., Kim, V. N., and Kataoka, N. (2002). Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell Biol. 3, 195–205.

Enomoto, A., Murakami, H., Asai, N., Morone, N., Watanabe, T., Kawai, K., Murakumo, Y., Usukura, J., Kaibuchi, K., and Takahashi, M. (2005). Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev. Cell 9, 389–402.

Enomoto, A., Ping, J., and Takahashi, M. (2006). Girdin, a novel actin-binding protein, and its family of proteins possess versatile functions in the Akt and Wnt signaling pathways. Ann. N Y Acad. Sci. 1086, 169–184.

Fedotov, S., and Iomin, A. (2007). Migration and proliferation dichotomy in tumor-cell invasion. Phys. Rev. Lett. 98, 118101.

Frame, M. C. (2004). Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 117, 989–998.

Garcia-Marcos, M., Ghosh, P., and Farquhar, M. G. (2009). GIV is a nonreceptor GEF for Ga alpha i with a unique motif that regulates Akt signaling. Proc. Natl. Acad. Sci. USA 106, 3178–3183.

Garcia-Marcos, M., Ghosh, P., Ear, J., and Farquhar, M. G. (2010). A structural determinant that renders Gna13 sensitive to activation by GIV/Girdin is re- quired to promote cell migration. J. Biol. Cell 285, 12765–12777.

Gaylarde, P. M., and Sarkany, I. (1975). Cell migration and DNA synthesis in culture organs of human skin. Br. J. Dermatol. 92, 375–380.

Gerhardt, H., et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163–1177.

Ghosh, P., Garcia-Marcos, M., Bornheimer, S. J., and Farquhar, M. G. (2008). Activation of Galphai3 triggers cell migration via regulation of GIV. J. Cell Biol. 182, 381–393.

Vol. 21, July 1, 2010 2353
Giese, A., Loo, M. A., Tran, N., Haskett, D., Coons, S. W., and Berens, M. E. (1996). Dichotomy of astrocytoma migration and proliferation. Int. J. Cancer 67, 275–282.

Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., and Mendelsohn, J. (1984). Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259, 7755–7760.

Hans, F., and Dimitrov, S. (2001). Histone H3 phosphorylation and cell division. Oncogene 20, 3021–3027.

Haugh, J. M. (2002). Localization of receptor-mediated signal transduction pathways: the inside story. Mol. Interv. 2, 292–307.

Hermouet, S., Merendino, J. J., Jr., Gutkind, J. S., and Spiegel, A. M. (1991). Activating and inactivating mutations of the alpha subunit of Gi2 protein have opposite effects on proliferation of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 88, 10455–10459.

Howlin, J., Rosenkvist, J., and Andersson, T. (2008). TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res. 10, R36.

Iyer, A. K., Tran, K. T., Griffith, L., and Wells, A. (2008). Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling. J. Cell Physiol. 214, 504–512.

Janes, K. A., and Lauffenburger, D. A. (2006). A biological approach to computational models of proteomic networks. Curr. Opin. Chem. Biol. 10, 73–80.

Jiang, P., Enomoto, A., Jijiwa, M., Kato, T., Hasegawa, T., Ishida, M., Sato, T., Asai, N., Murakumo, Y., and Takahashi, M. (2008). An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 68, 1310–1318.

Kitamura, T., et al. (2008). Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat. Cell Biol. 10, 329–337.

Kloth, M. T., Laughlin, K. K., Biscardi, J. S., Boerner, J. L., Parsons, S. J., and Silva, C. M. (2003). STAT5b, a mediator of synergism between c-src and the epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 100, 17615–17622.

Luttrell, L. M., Daaka, Y., and Lefkowitz, R. J. (1999). Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177–183.

Mandel, H. G., and Rall, D. P. (1969). The present status of cancer chemotherapy—a summary of papers delivered at the Cherry Hill Conference on “a critical evaluation of cancer chemotheraphy”. Cancer Res. 29, 2478–2485.

Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., and Bunnett, N. W. (2009). Endosomes: a legitimate platform for the signaling train. Proc. Natl. Acad. Sci. USA 106, 17613–17622.

Noma, T., et al. (2007). Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445–2458.

Ohman, L., Franzen, L., Rudolph, U., Birnbaumer, L., and Hornquist, E. H. (2002). Regression of Peyer’s patches in G alpha i2 deficient mice prior to colitis is associated with reduced expression of Bcl-2 and increased apoptosis. Gut 51, 392–397.

Qiao, M., Iglehart, J. D., and Pardee, A. B. (2007). Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res. 67, 5293–5299.

Razi, M., and Futter, C. E. (2006). Distinct roles for Tsg101 and Hrs in multivesicular body formation and inward vesiculation. Mol. Biol. Cell 17, 3469–3483.

Rijken, P. J., Hage, W. J., van Bergen en Henegouwen, P. M., Verkleij, A. J., and Boonstra, J. (1991). Epidermal growth factor induces rapid reorganization of the actin microfilament system in human A431 cells. J. Cell Sci. 100, 491–499.

Schlessinger, J. (2002). Ligand-induced, receptor-mediated dimerization and activation of EGFR receptor. Cell 110, 669–672.

Simpson, F., Martin, S., Evans, T. M., Kerr, M., James, D. E., Parton, R. G., Teasdale, R. D., and Wicking, C. (2005). A novel hook-related protein family and the characterization of hook-related protein 1. Traffic 6, 442–458.

Srebrow, A., and Kamlehlt, A. R. (2006). The connection between splicing and cancer. J. Cell Sci. 119, 2635–2641.

Stickeler, E., Kittrell, F., Medina, D., and Berger, S. M. (1999). Stage-specific changes in SR splicing factors and alternative splicing in mammmary tumorigenesis. Oncogene 18, 3574–3582.

Tetreault, M. P., Chailler, P., Beaulieu, J. F., Rivard, N., and Menard, S. (2007). Epidermal growth factor receptor-dependent PI3K-activation promotes restitution of wounded human gastric epithelial monolayers. J. Cell Physiol. 214, 545–557.

Tice, D. A., Biscardi, J. S., Nickles, A. L., and Parsons, S. J. (1999). Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96, 1415–1420.

Ware, M. F., Tice, D. A., Parsons, S. J., and Lauffenburger, D. A. (1997). Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor. J. Biol. Chem. 272, 30185–30190.

Waters, C., Pyne, S., and Pyne, N. J. (2004). The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin. Cell Dev. Biol. 15, 292–307.

Weber, G. F. (2008). Molecular mechanisms of metastasis. Cancer Lett. 270, 181–190.

Wells, A., Kassis, J., Solava, J., Turner, T., and Lauffenburger, D. A. (2002). Growth factor-induced cell motility in tumor invasion. Acta Oncol. 41, 124–130.